MOSAIC II: MAP Wound Matrix to speed graft readiness after non-melanoma skin cancer surgery
Official title: MOSAIC II: A Randomized Clinical Study of the MAP Wound Matrix to Reduce Time to Graft-Readiness after Non-Melanoma Skin Cancer Resection
Funded at Tempo Therapeutics, INC. · NIH-11406980 · Data updated 2026-11-12
A randomized trial tests a moldable wound scaffold (MAP Wound Matrix) to speed healing and time to graft-ready skin after head and neck cancer surgeries in adults.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tempo Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | September 18, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,423,186 |
| NIH project number | 1R44CA314892-01 |
| Project ID | NIH-11406980 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older with post-resection head-and-neck wounds with exposed bone following non-melanoma skin cancer surgery.
✕Less likely to help
Patients without wounds meeting the specified criteria or those who do not respond to scaffold-based healing may see no benefit.
What this research studies
This trial tests a bioresorbable MAP Wound Matrix designed to fit complex head-and-neck wounds after non-melanoma skin cancer removal. It builds on prior human use and aims to show whether the scaffold reduces the time until the wound is ready for grafting, improves healing, and lowers complications. The study will manufacture clinical-grade material under stringent manufacturing standards and assess safety and efficacy in a multicenter, randomized design with blinded assessment of wound healing. Participants will be adults with post-resection wounds and will be assigned to MAP or a comparator to compare outcomes over several weeks. Results will inform regulatory steps and potential clinical adoption if successful.
Why it matters
Potential benefit: If successful, patients could experience faster wound healing, fewer complications, and quicker readiness for grafting after head-and-neck cancer surgery.
How similar studies have gone: Earlier feasibility work with MAP Wound Matrix has shown promise, and this study seeks to confirm safety and efficacy in a larger, randomized setting.
Where this research is happening
-
Tempo Therapeutics, INC.
San Diego, United States Active
Researchers
- Principal investigator: Deshayes, Stephanie — Tempo Therapeutics, INC.
- Study coordinator: Deshayes, Stephanie
Related research
Other NIH-funded projects on the same topics.
-
CivaDerm: a new four-day skin cancer radiation bandage
A new four‑day radiation bandage for non-melanoma skin cancer aims to treat facial and other areas without multiple clinic visits or big scars.
-
Low-energy skin radiation patches for treating non-melanoma skin cancer
A patient-friendly device idea uses a patch to deliver a tiny amount of radiation right at the skin to treat non-melanoma skin cancer in as few visits.
-
Safer medicines to prevent basal and squamous (non‑melanoma) skin cancer
Researchers are developing new, non‑toxic oral rexinoid medicines aimed at preventing basal cell and squamous cell skin cancers, especially for people with weakened immune systems like organ transplant recipients.
-
Creating safe drugs to prevent non-melanoma skin cancer
This study is working on new medications to help prevent skin cancer in people with weakened immune systems, like those who have had organ transplants, by creating safer and more effective options that don’t have the usual side effects of current treatments.
-
New ways to prevent non-melanoma skin cancer
This study is looking for new ways to help prevent non-melanoma skin cancers, like basal cell and squamous cell carcinoma, by understanding how these cancers develop and testing new treatments that could lower your risk.
-
Advancing Treatments for Melanoma and Skin Cancer
This program is looking for new and better ways to treat melanoma and other skin cancers, especially when current treatments aren't enough.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.